/PRNewswire/ Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering first-in-class novel therapies for atrial fibrillation ("AF"), the.
A company says it is developing a small molecule drug without major safety issues to treat a growing number of cases of atrial fibrillation, the most common cardiac arrhythmia.
/PRNewswire/ Acesion Pharma ("Acesion"), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation ("AF"), the most common cardiac.
Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the most common cardiac arrhythmia, today announced positive data from its Phase 2 trial of AP30663, a first-in-class SK ion channel inhibitor for conversion of AF to normal sinus rhythm. The trial .